Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Treatment Strategies for Relapsed/Refractory MCL Represent a Unique Challenge

February 8th 2022

Despite the breakthroughs in the development of therapeutic regimens for patients with mantle cell lymphoma, variability in treatment pathways presents a unique hurdle in determining the appropriate course of care following disease progression.

Dr. Phillips on the Current Role of Ibrutinib in MCL

February 3rd 2022

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Incyte Withdraws NDA for Parsaclisib in Relapsed/Refractory Follicular Lymphoma, MZL, MCL

January 26th 2022

The global biopharmaceutical company Incyte has decided to withdraw the new drug application for parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

January 21st 2022

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Second-Line Therapy for MCL: Differentiating Available BTK Inhibitors

January 21st 2022

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management

January 20th 2022

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

Dr. Phillips Discusses Ongoing Research With BTK Inhibitors in MCL

January 19th 2022

Tycel Jovelle Phillips, MD, discusses ongoing research with BTK inhibitors in mantle cell lymphoma.

Dr. McKinney on the Potential for Curative-Intent Therapies in MCL

January 18th 2022

Matthew S. McKinney, MD, discusses the potential for curative-intent therapies in mantle cell lymphoma.

Ibrutinib/Rituximab Combo Represents Effective Chemo-Free Option for Elderly Patients with MCL

January 13th 2022

The combination of ibrutinib and rituximab produced a high overall response rate and durable survival in elderly patients with mantle cell lymphoma.

MB-106 Elicits Durable Responses and Demonstrates Tolerable Safety Profile in DLBCL, MCL, Follicular Lymphoma

January 13th 2022

Mazyar Shadman, MD, MPH, discusses the utility of MB-106 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia.

Zilovertamab Plus Ibrutinib Under Further Evaluation in Relapsed/Refractory MCL

January 12th 2022

The FDA has agreed upon key elements, including design features and operational details, for the phase 3 ZILO-301 trial, which will evaluate zilovertamab in combination with ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

Dr. Riedell on Unique Data Points from an Analysis in MCL

January 11th 2022

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Dr. Phillips on Considering Age During Treatment Selection With BTK Inhibitors in MCL

January 10th 2022

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Dr. Heyman on the Evolution of BTK Inhibitors in Relapsed/Refractory MCL

January 5th 2022

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Phillips on Navigating Treatment Selection With BTK Inhibitors in MCL

January 3rd 2022

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL

December 23rd 2021

Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.

Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCL

December 23rd 2021

Expert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.

Dr. Riedell on an Analysis Evaluating the Effect of Time to Relapse on OS in MCL

December 22nd 2021

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Dr. Heyman on Ibrutinib Plus Venetoclax in Relapsed/Refractory MCL

December 21st 2021

Benjamin Heyman, MD, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma.

Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL

December 21st 2021

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.